AI Model Predicts Glioblastoma Infiltration Beyond Visible Tumor Margins

Glioblastoma remains the most lethal primary brain malignancy, characterized by a median survival of 12 to 15 months and nearly universal recurrence [1, 2]. While maximal safe resection and chemoradiotherapy are standard, treatment failure often stems from microscopic tumor cells that infiltrate the brain parenchyma well beyond the contrast-enhancing margins visible on standard MRI [3]. Current imaging techniques frequently struggle to distinguish between true tumor progression and pseudoprogression (treatment-related inflammatory changes that mimic tumor growth), a diagnostic challenge where artificial intelligence algorithms have demonstrated a pooled sensitivity of 88% (95% CI, 77% to 100%) in high-grade gliomas [4, 5, 6]. Although advanced sequences such as diffusion-weighted imaging (an MRI technique that measures the random motion of water molecules to infer tissue cellularity) offer insights into intratumoral heterogeneity, they have not yet solved the problem of mapping diffuse infiltration for surgical planning [3]. The SupraGlio trial recently evaluated GlioMap, a computational model that identifies high-risk regions of recurrence before they become visible on conventional scans, achieving an accuracy of 0.81 (95% CI, 0.71 to 0.91) and an AUC of 0.84 for histologically confirmed infiltration [7].